---
title: "Unity Biotechnology Approves Company Liquidation Plan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/258149914.md"
description: "Unity Biotechnology has approved a liquidation plan following a special stockholder meeting on September 18, 2025. Stockholders voted in favor of the Dissolution Proposal, allowing the Board of Directors to proceed with the dissolution. The current analyst rating for UNBX stock is a Hold with a $2.00 price target, but Spark's AI Analyst rates it as Underperform due to financial challenges and a bearish trend. Unity Biotechnology focuses on developing therapeutics for aging-related diseases and has a market cap of $998.3K."
datetime: "2025-09-19T21:18:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/258149914.md)
  - [en](https://longbridge.com/en/news/258149914.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/258149914.md)
---

# Unity Biotechnology Approves Company Liquidation Plan

Unity Biotechnology ( (UNBX) ) has shared an announcement.

On September 18, 2025, Unity Biotechnology held a special meeting of stockholders where the approval of the company’s liquidation and dissolution was voted on. The stockholders approved both the Dissolution Proposal and the Adjournment Proposal, granting the Board of Directors the authority to proceed with the dissolution at their discretion.

The most recent analyst rating on (UNBX) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Unity Biotechnology stock, see the UNBX Stock Forecast page.

**Spark’s Take on UNBX Stock**

According to Spark, TipRanks’ AI Analyst, UNBX is a Underperform.

Unity Biotechnology’s overall score is weighed down by significant financial challenges, including persistent losses and negative equity. Technical analysis suggests a bearish trend with limited momentum. Valuation metrics reflect the unprofitability of the company. However, the recent strategic appointment to the Board provides a potential strategic advantage in its program development.

To see Spark’s full report on UNBX stock, click here.

**More about Unity Biotechnology**

Unity Biotechnology, Inc. operates in the biotechnology industry, focusing on the development of therapeutics to slow, halt, or reverse diseases of aging.

**Average Trading Volume:** 581,294

**Technical Sentiment Signal:** Sell

**Current Market Cap:** $998.3K

### Related Stocks

- [UBX.US](https://longbridge.com/en/quote/UBX.US.md)

## Related News & Research

- [uBriGene and Cellinfinity BIO collaborate to accelerate in vivo CAR-T therapies](https://longbridge.com/en/news/281159926.md)
- [Will a Kevin Warsh-Led Fed Sink the Stock Market? Here's What the Puzzle Pieces Suggest.](https://longbridge.com/en/news/286879308.md)
- [HealthView CEO Steven Gonzalez Announces Inc. Articles on Why Presence Beats Certainty — and Why It Matters Even More in the Age of AI](https://longbridge.com/en/news/286959260.md)
- [09:06 ETHarmony Comes to the Massachusetts State House as The Platters® Prepare Their Musical Love Letter to the World](https://longbridge.com/en/news/286918739.md)
- [15:21 ETTEAMSTERS AT BIMBO BAKERIES RATIFY NEW AGREEMENT](https://longbridge.com/en/news/286810426.md)